| Gene symbol | HLA-G | Synonyms | MHC-G | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p22.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | major histocompatibility complex, class I, G | ||||
| GTO ID | GTC3679 |
| Trial ID | NCT06150885 |
| Disease | Solid Tumor |
| Altered gene | HLA-G |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR001 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Single Arm, Open Label, Dose-escalation Phase I and Dose-expansion Phase IIa Clinical Study to Evaluate the Feasibility, Safety, and Efficacy of Allogeneic Chimeric Antigen Receptor (CAR) Gamma-Delta T Cells CAR001 in Subjects With Relapsed/Refractory Solid Tumors |
| Year | 2024 |
| Country | China |
| Company sponsor | Ever Supreme Bio Technology Co., Ltd. |
| Other ID(s) | ES-CCAR01-A3301 |
| Cohort 1 | |||||||||
|
|||||||||